Your browser doesn't support javascript.
loading
Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1.
Mease, Philip J; van der Heijde, Désirée; Ritchlin, Christopher T; Okada, Masato; Cuchacovich, Raquel S; Shuler, Catherine L; Lin, Chen-Yen; Braun, Daniel K; Lee, Chin H; Gladman, Dafna D.
Afiliación
  • Mease PJ; Department of Rheumatology, Swedish Medical Center, and University of Washington, Seattle, Washington, USA.
  • van der Heijde D; Department of Rheumatology, Leiden University Medical Centre, Leiden, The Netherlands.
  • Ritchlin CT; Allergy, Immunology, & Rheumatology Division, University of Rochester Medical Center, Rochester, New York, USA.
  • Okada M; Immuno-Rheumatology Center, St. Luke's International Hospital, Tokyo, Japan.
  • Cuchacovich RS; Eli Lilly and Company, Indianapolis, Indiana, USA.
  • Shuler CL; Rheumatology Division, Department of Medicine, Indiana University School of Medicine, Indianapolis, Indiana, USA.
  • Lin CY; Eli Lilly and Company, Indianapolis, Indiana, USA.
  • Braun DK; Eli Lilly and Company, Indianapolis, Indiana, USA.
  • Lee CH; Eli Lilly and Company, Indianapolis, Indiana, USA.
  • Gladman DD; Eli Lilly and Company, Indianapolis, Indiana, USA.
Ann Rheum Dis ; 76(1): 79-87, 2017 Jan.
Article en En | MEDLINE | ID: mdl-27553214
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Artritis Psoriásica / Antirreumáticos / Anticuerpos Monoclonales Humanizados / Adalimumab Tipo de estudio: Clinical_trials Límite: Adult / Female / Humans / Male / Middle aged Idioma: En Revista: Ann Rheum Dis Año: 2017 Tipo del documento: Article País de afiliación: Estados Unidos
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Artritis Psoriásica / Antirreumáticos / Anticuerpos Monoclonales Humanizados / Adalimumab Tipo de estudio: Clinical_trials Límite: Adult / Female / Humans / Male / Middle aged Idioma: En Revista: Ann Rheum Dis Año: 2017 Tipo del documento: Article País de afiliación: Estados Unidos